Skip to main
RXST

RxSight (RXST) Stock Forecast & Price Target

RxSight (RXST) Analyst Ratings

Based on 8 analyst ratings
Hold
Strong Buy 13%
Buy 0%
Hold 63%
Sell 25%
Strong Sell 0%

Bulls say

RxSight is positioned for long-term success due to its innovative and differentiated technology, including the collaboration with ALC that could potentially generate significant milestone payments and royalty payments. Risks to consider include limited adoption due to the need for additional capital equipment, competition, and a potential for dilutive financing. The company has a strong growth potential with its 12-month price target of $11, which is backed by an EV/sales multiple of 1.5x our 2027 sales estimate.

Bears say

RxSight is experiencing underlying weakness in their 2nd quarter results and a decline in sales of their Light Adjustable Lenses (LAL) due to competitive trialing, likely from JNJ's PureSee product. This led to a revenue miss and a downward revision of 2026 revenue guidance to $140-160M. Additionally, the company's high cash burn remains a concern as they continue to invest in developing new LAL products.

RxSight (RXST) has been analyzed by 8 analysts, with a consensus rating of Hold. 13% of analysts recommend a Strong Buy, 0% recommend Buy, 63% suggest Holding, 25% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of RxSight and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About RxSight (RXST) Forecast

Analysts have given RxSight (RXST) a Hold based on their latest research and market trends.

According to 8 analysts, RxSight (RXST) has a Hold consensus rating as of Sep 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

RxSight (RXST)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.